Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Syneron Medical Ltd Receives FDA Clearance For Abdominal Circumferential Reduction And CE Mark For New Velashape III Platform


Wednesday, 11 Sep 2013 09:00am EDT 

Syneron Medical Ltd announced that Food and Drug Administration (FDA) clearance and CE mark approval for VelaShape III 1, the Company's new non-invasive body shaping platform. This new platform is effective for temporary reduction in circumference of the abdomen and is also used in a wide range of other body shaping applications such as cellulite treatments. 

Related Company News

Company Quote

9.86
-0.12 -1.20%
20 Aug 2014